التفاصيل البيبلوغرافية
| العنوان: |
Functional Precision Medicine Successfully Guides Therapeutic Regimen of 'Cancer of Unknown Primary' Later Classified as Triple-Negative Breast Cancer: A Case Report. |
| المؤلفون: |
Ruhe, Larissa, Heibl, Sonja, Czompo, Manfred, Haybaeck, Johannes, Loskutov, Jürgen, Regenbrecht, Manuela Johanna, Thaler, Josef, Wedeken, Lena, Regenbrecht, Christian René Alexander |
| المصدر: |
Case Reports in Oncology; 2024, Vol. 17 Issue 1, p490-496, 7p |
| مصطلحات موضوعية: |
TRIPLE-negative breast cancer, CANCER of unknown primary origin, INDIVIDUALIZED medicine, PHYSICIANS, LYMPHATIC metastasis |
| مستخلص: |
Introduction: Controlled randomized trials, molecular analytics, and guideline recommendations have so far been irreplaceable tools to ensure appropriate treatment and decision-making for physicians and patients. Individual patient models are increasingly complementing these methods, particularly in the case of advanced cancers, rare cancers, and cancers of unknown primary (CUP), as in these cases comprehensive clinical evidence is unavailable, often resulting in poor treatment success, even after stratification. Case Presentation: Here we report a 53-year-old patient with CUP with axillary lymph node metastases for whom patient-derived 3D (PD3D®) tumor organoids successfully guided personalized treatment. PD3D tumor models were used to screen drugs that are effective at the suspected primary tumor site. The screen revealed sensitivity to doxorubicin, which is not indicated for CUP treatment but hinted toward breast cancer that was subsequently confirmed as triple-negative breast cancer (TNBC). The patient showed partial remission to first-line doxorubicin and cyclophosphamide, which were followed by docetaxel. Subsequent radiotherapy eventually led to a complete remission, which is still ongoing. Conclusion: We conclude that pre-therapeutic drug sensitivity screening with PD3D tumor models can be essential in guiding and enabling an effective personalized treatment for patients with hard-to-treat cancers, like CUP or TNBC. [ABSTRACT FROM AUTHOR] |
|
Copyright of Case Reports in Oncology is the property of Karger AG and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder